Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Annals of Surgical Oncology|April 8, 2014
Locoregional disease patterns in well-differentiated and dedifferentiated retroperitoneal liposarcoma: implications for the extent of resection?William W Tseng, John E Madewell, Wei Wei, et al.
Annals of Surgical Oncology|May 27, 2011
Diagnosis, management, and outcome of patients with dedifferentiated liposarcoma systemic metastasisMarkus P Ghadimi, Tariq Al-Zaid, John Madewell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2012
Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumorsMarkus P Ghadimi, Eric D Young, Roman Belousov, et al.
Molecular Cancer Therapeutics|August 1, 2012
Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumorsMarkus P Ghadimi, Gonzalo Lopez, Keila E Torres, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 25, 2011
Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcomaElizabeth G Demicco, Keila E Torres, Markus P Ghadimi, et al.
The Journal of Pathology|August 10, 2011
Increased midkine expression correlates with desmoid tumour recurrence: a potential biomarker and therapeutic targetChiara Colombo, Chad J Creighton, Markus P Ghadimi, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|September 17, 2015
Peritoneal sarcomatosis: site of origin for the establishment of an in vitro and in vivo cell line model to study therapeutic resistance in dedifferentiated liposarcomaSabrina Mersch, Jasmin C Riemer, Philipp M Schlünder, et al.
Cancer|May 21, 2011
Pleomorphic liposarcoma: clinical observations and molecular variablesMarkus P Ghadimi, Ping Liu, Tingsheng Peng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2011
Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumorsKeila E Torres, Quan-Sheng Zhu, Katelynn Bill, et al.
Pageof 1